Isorhapontigenin protects against doxorubicin-induced cardiotoxicity via increasing YAP1 expression.

MLA

Wang, Panxia, et al. “Isorhapontigenin Protects against Doxorubicin-Induced Cardiotoxicity via Increasing YAP1 Expression.” Acta Pharmaceutica Sinica. B, vol. 11, no. 3, Mar. 2021, pp. 680–93. EBSCOhost, https://doi.org/10.1016/j.apsb.2020.10.017.

APA

Wang, P., Wang, M., Hu, Y., Chen, J., Cao, Y., Liu, C., Wu, Z., Shen, J., Lu, J., & Liu, P. (2021). Isorhapontigenin protects against doxorubicin-induced cardiotoxicity via increasing YAP1 expression. Acta Pharmaceutica Sinica. B, 11(3), 680–693. https://doi.org/10.1016/j.apsb.2020.10.017

Chicago

Wang, Panxia, Minghui Wang, Yuehuai Hu, Jianxing Chen, Yanjun Cao, Cui Liu, Zhongkai Wu, Juan Shen, Jing Lu, and Peiqing Liu. 2021. “Isorhapontigenin Protects against Doxorubicin-Induced Cardiotoxicity via Increasing YAP1 Expression.” Acta Pharmaceutica Sinica. B 11 (3): 680–93. doi:10.1016/j.apsb.2020.10.017.